Immunology Program

The Michel Sadelain Lab

Research

Michel Sadelain, MD, PhD

Stephen and Barbara Friedman Chair; Director, Center for Cell Engineering

My lab studies the mechanisms governing transgene expression, stem cell engineering, and genetic strategies to enhance immunity against cancer.

View Lab Overview

Featured News

Clinical Trial for Beta-Thalassemia Brings Important Insights for Treating Blood Disorders with Stem Cell Gene Therapy

Thursday, January 6, 2022

A gene therapy approach could prove effective at treating an inherited blood disorder called beta (β)-thalassemia.

In the Lab

A New Target for CAR T Cells: Senescence-Related Diseases

Wednesday, June 17, 2020

From atherosclerosis and diabetes to liver fibrosis and osteoarthritis, senescent cells are at the root of many debilitating diseases. Scientists increasingly have them in the crosshairs.

World-Renowned Immunologist Michel Sadelain Wins Pasteur-Weizmann/Servier Prize

Tuesday, October 16, 2018

Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at MSK, has been awarded the Pasteur-Weizmann/Servier International Prize. Dr. Sadelain was chosen in recognition of his pivotal research demonstrating the therapeutic potential of engineered T cells.

View All Featured News

Publications

Cabriolu A, Odak A, Zamparo L, Yuan H, Leslie CS, and Michel Sadelain. Globin vector regulatory elements are active in early hematopoietic progenitor cells. Molecular Therapy. March 2, 2022. [PMID: 35247584]

Mansilla-Soto J, Eyquem J, Haubner S, Hamieh M, Feucht J, Paillon N, Zucchetti AE, Li Z, Sjöstrand M, Lindenbergh PL, Saetersmoen M, Dobrin A, Maurin M, Iyer A, Garcia Angus A, Miele MM, Zhao Z, Giavridis T, van der Stegen SJC, Tamzalit F, Rivière I, Huse M, Hendrickson RC, Hivroz C, and Sadelain M. HLA-independent T cell receptors for targeting tumors with low antigen density. Nature Medicine. January 13, 2022. [PMID: 35027758]

Boulad F, Maggio A, Wang X, Moi P, Acuto S, Kogel F, Takpradit C, Prockop S, Mansilla-Soto J, Cabriolu A, Odak A, Qu J, Thummar K, Du F, Shen L, Raso S, Barone R, Di Maggio R, Pitrolo L, Giambona A, Mingoia M, Everett JK, Hokama P, Roche AM, Cantu VA, Adhikari H, Reddy S, Bouhassira E, Mohandas N, Bushman FD, Rivière I and Sadelain M. Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial. Nature Medicine. January 3, 2022. [PMID: 34980909]

Amor, C., Feucht, J., Leibold, J. et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 2020 Jul;583(7814):127-132. [PMID: 32555459]

Hamieh M, Dobrin A, Cabriolu A, van der Stegen SJC, Giavridis T, Mansilla-Soto J, Eyquem J, Zhao Z, Whitlock BM, Miele MM, Li Z, Cunanan KM, Huse M, Hendrickson RC, Wang X, Rivière I, Sadelain M. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019 Apr;568(7750):112-116. [PMID: 30918399]

View All Publications

People

Michel Sadelain, MD, PhD

Stephen and Barbara Friedman Chair; Director, Center for Cell Engineering

Immunologist Michel Sadelain studies the mechanisms governing transgene expression, stem cell engineering, and genetic strategies to enhance immunity against cancer.
MD, University of Paris
PhD, University of Alberta

m-sadelain@ski.mskcc.org: Email Address
View physician profile: Physician profile

Members

Andreina Garcia Angus
Senior Research Technician

Gertrude Gunset
Senior Research Assistant

Sascha Haubner
Senior Research Scientist

Nayan Jain, B. Tech — Nayan Jain
Graduate Student

Ivan Kotchetkov
Instructor, Neuro-oncology

Michael A. Lopez
Bioinformatics Engineer

Jorge Mansilla-Soto
Senior Research Scientist

Michelle Saetersmoen
Visiting Investigator

Maria Lemdal Sjostrand
Visiting Investigator

Sjoukje Van der Stegen — Sjoukje van der Stegen
Research Associate

Ophelie L. Vivier
Graduate research Assistant

Lab Alumni

Adam Bogard, MD — Adam Bogard
Research Fellow

Pictured: Rosaria Cristantielli — Rosaria Cristantielli
Research Fellow

Marco L. Davila, MD, PhD — Marco L. Davila
Assistant Member

Victor Fedorov

Graduate Student

Leda Ferro

Visiting Graduate Student

Leszek Lisowski

Graduate Student

John Markley

MD/PhD Student

Marcela Maus, MD, PhD — Marcela Maus
Medicine Fellow

Eirini Papapetrou, MD, PhD — Eirini Papapetrou
Research Associate

Lindsay Pharmer, MD — Lindsay Pharmer
Research Fellow

Jason Plotkin
Senior Research Technician

Maria Themeli, MD — Maria Themeli
Research Fellow

Lab Affiliations

Achievements

Recipient of the American Society of Gene & Cell Therapy Outstanding Achievement Award (2021)
Inserm International Prize, Paris, France (2019)
Jacob and Louise Gabbay Award in Biotechnology and Medicine (2019)
Pasteur Weizmann/Servier Prize at the Academy of Sciences in Paris (2018)
Cited in Science magazine "Breakthrough of the Year: Cancer Immunology” (2013)

Sultan Bin Khalifa International Thalassemia Awards (SITA) International Award for Innovative Medical Research on Thalassemia (2013)
Elected to Vice President of the American Society for Gene and Cell Therapy (Vice President 2013, President Elect 2014, President 2015)
Antonio Cao Award for Research in Thalassemia or Hemoglobinopathies, Palermo, Italy (2013)
Recipient of the Coley Award of the Cancer Research Institute for Distinguished Research in Tumor Immunology (shared with Carl June, University of Pennsylvania) (2012)
Member, Grant Review Committee and Strategic Committee, CIRM (2011)
Incumbent of the Stephen and Barbara Friedman Chair (2007)
V Foundation Award in Honor of Mayor Rudolph Guliani (2005)

Get in Touch

m-sadelain@ski.mskcc.org

Lab Head Email
917-432-2340

Office Fax
212-639-6170

Lab Phone
917-432-2340

Lab Fax

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Michel Sadelain discloses the following relationships and financial interests:

Atara Biotherapeutics
Intellectual Property Rights
Ceramedix
Intellectual Property Rights
Fate Therapeutics
Intellectual Property Rights; Ownership / Equity Interests; Provision of Services (uncompensated)
Juno Therapeutics
Intellectual Property Rights
Minerva Biotechnologies
Intellectual Property Rights; Ownership / Equity Interests; Provision of Services (uncompensated)

Mnemo Therapeutics
Intellectual Property Rights; Ownership / Equity Interests; Provision of Services (uncompensated)
NHLBI Gene Therapy Resource Program
Provision of Services (uncompensated)
St. Jude Children's Research Hospital
Provision of Services
Takeda Pharmaceuticals
Intellectual Property Rights; Provision of Services
Y-mAbs Therapeutics, Inc.
Intellectual Property Rights

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.

View all disclosures